Clinico-Metabolic Profiling Unraveled Key Metabolic Alterations Underlying the Pathophysiology of Chronic Myeloid

Surbhi Gupta1, Nitu Nigam1, Shailendra Prasad Verma1

  • 1King George's Medical University (KGMU), Lucknow 226003, UP, India.

ACS Omega
|May 4, 2026
PubMed

Insights

Serum metabolomics reveals distinct metabolic profiles in chronic myeloid leukemia (CML). Key amino acids and glucose are downregulated in CML patients, suggesting potential as novel biomarkers for early diagnosis and targeted therapies.

Area of Science:

  • Biochemistry
  • Oncology
  • Metabolomics

Background:

  • Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
  • Tyrosine kinase inhibitors (TKIs) are effective but face challenges with resistance and progression.
  • Novel biomarkers are needed for early diagnosis, understanding CML, and developing new therapies.

Purpose of the Study:

  • To analyze serum metabolic profiles in newly diagnosed, treatment-naive CML patients compared to healthy controls.
  • To identify potential noninvasive biomarkers for CML diagnosis and therapeutic strategies.

Main Methods:

  • Serum samples from 30 CML patients and 20 healthy controls were analyzed using 1H nuclear magnetic resonance (NMR) spectroscopy.
  • Multivariate and univariate statistical analyses were employed to identify metabolic differences.
  • Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic performance.

Main Results:

  • Significant metabolic disparities were observed between CML patients and controls, particularly in amino acid and energy metabolism.
  • Eight key metabolites (histidine, alanine, valine, glutamine, tyrosine, serine, glucose, isoleucine) were consistently downregulated in CML.
  • These downregulated metabolites reflect enhanced cellular uptake and metabolic rewiring in leukemic proliferation.
  • ROC analysis showed promising discriminatory ability, with several metabolites achieving an area under the ROC curve (AUROC) > 0.90.

Conclusions:

  • Serum metabolomics reveals a distinct CML signature associated with increased bioenergetic/biosynthetic demands and immune evasion.
  • Downregulated amino acids and altered glucose metabolism highlight potential therapeutic vulnerabilities.
  • Serum metabolic profiles show promise as noninvasive biomarkers for CML, aiding future metabolism-targeted therapies.

Related Concept Videos